ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy

Annals of Oncology

Volumn 22, Issue 3, 2011, Pages 575-581

  Besse, B ^a   Massard, C ^a   Haddad, V ^a   Andre, F ^a   Dunant, A ^a   Pirker, R ^b   Olaussen, K A ^a   Brambilla, E ^c   Fouret, P ^a   Soria, J C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c HÔPITAL MICHALLON   (France)

Author keywords

Adjuvant chemotherapy; Brain metastasis; Cisplatin; ERCC1; Lung cancer; Randomised trial

Indexed keywords

CISPLATIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; VINCA ALKALOID;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER MORPHOLOGY; CONTROLLED STUDY; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; INCIDENCE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROMETASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 79952018711     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq407     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Stewart LA, Burdett S, Tierney JF et al. Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small cell lung cancer (NSCLC): a metaanalysis using individual patient data (IPD) from randomized clinical trials (RCT). J Clin Oncol (Meeting Abstracts) 2007; 25: 7552.
3. Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26: 3552-3559.
4. International Adjuvant Lung Cancer Trial Collaborative Group, Arriagada R, Bergman B et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360.
5. Arriagada R, Dunant A, Pignon JP et al. Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010; 28: 35-42.
6. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-2597.
7. Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-727.
8. Vincent MD, Butts C, Seymour L et al. Updated survival analysis of JBR.10: a randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2009; 27: 7501.
9. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991.
10. Dunant A, Pignon JP, Le Chevalier T. Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial. Clin Cancer Res 2005; 11: 5017s-5021s.
11. Nathoo N, Chahlavi A, Barnett GH et al. Pathobiology of brain metastases. J Clin Pathol 2005; 58: 237-242.
12. Andre F, Grunenwald D, Pujol JL et al. Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered? Cancer 2001; 91: 2394-2400.
13. Robnett TJ, Machtay M, Stevenson JP et al. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol 2001; 19: 1344-1349.
14. Wang SY, Ye X, Ou W et al. Risk of cerebral metastases for postoperative locally advanced non-small-cell lung cancer. Lung Cancer 2009; 64: 238-243.
15. de Vries NA, Beijnen JH, Boogerd W et al. Blood-brain barrier and chemotherapeutic treatment of brain tumors. Expert Rev Neurother 2006; 6: 1199-1209.
16. Carolan H, Sun AY, Bezjak A et al. Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection? Lung Cancer 2005; 49: 109-115.
17. Ceresoli GL, Reni M, Chiesa G et al. Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis. Cancer 2002; 95: 605-612.
18. Mamon HJ, Yeap BY, Janne PA et al. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 2005; 23: 1530-1537.
19. Law A, Karp DD, Dipetrillo T et al. Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced nonsmall cell lung carcinoma. Cancer 2001; 92: 160-164.
20. Betticher DC, Hsu Schmitz SF, Totsch M et al. Prognostic factors affecting longterm outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006; 94: 1099-1106.
21. Chen AM, Jahan TM, Jablons DM et al. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer 2007; 109: 1668-1675.
22. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
23. Clayton AJ, Danson S, Jolly S et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91: 639-643.
24. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007; 13: 1648-1655.
25. Bhagwat NR, Roginskaya VY, Acquafondata MB et al. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res 2009; 69: 6831-6838.
26. Olaussen KA, Fouret P, Kroemer G. ERCC1-specific immunostaining in nonsmall-cell lung cancer. N Engl J Med 2007; 357: 1559-1561.
27. Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999; 341: 476-484.
28. Slotman BJ, Mauer ME, Bottomley A et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms--results of an International Phase III Randomized Controlled Trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol 2009; 27: 78-84.
29. Cox JD, Stanley K, Petrovich Z et al. Cranial irradiation in cancer of the lung of all cell types. JAMA 1981; 245: 469-472.
30. Russell AH, Pajak TE, Selim HM et al. Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1991; 21: 637-643.
31. Gore EM, Bae K, Wong S et al. A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: Initial analysis of Radiation Therapy Oncology Group 0214. J Clin Oncol (Meeting Abstracts) 2009; 27: 7506.